Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 4 | 2014 | 332 | 0.900 |
Why?
|
| Apoptosis | 8 | 2014 | 1641 | 0.880 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2020 | 17 | 0.730 |
Why?
|
| Home Care Services | 1 | 2020 | 84 | 0.700 |
Why?
|
| NF-kappa B | 3 | 2014 | 432 | 0.700 |
Why?
|
| Cancer Survivors | 1 | 2022 | 146 | 0.680 |
Why?
|
| Palliative Care | 2 | 2020 | 271 | 0.670 |
Why?
|
| Acetylcysteine | 2 | 2014 | 296 | 0.580 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 778 | 0.520 |
Why?
|
| Glutathione | 4 | 2014 | 343 | 0.480 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.470 |
Why?
|
| Signal Transduction | 5 | 2014 | 2689 | 0.440 |
Why?
|
| Mitochondria | 3 | 2005 | 643 | 0.360 |
Why?
|
| Hypoxia | 3 | 2007 | 169 | 0.350 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 47 | 0.290 |
Why?
|
| Glutaredoxins | 3 | 2013 | 12 | 0.280 |
Why?
|
| Stroke | 4 | 2021 | 2163 | 0.260 |
Why?
|
| Catechin | 1 | 2005 | 26 | 0.250 |
Why?
|
| Membrane Potentials | 1 | 2005 | 200 | 0.240 |
Why?
|
| Azacitidine | 1 | 2003 | 20 | 0.220 |
Why?
|
| Telemedicine | 3 | 2021 | 700 | 0.220 |
Why?
|
| Gene Silencing | 1 | 2003 | 137 | 0.210 |
Why?
|
| Antioxidants | 1 | 2005 | 304 | 0.210 |
Why?
|
| Caregivers | 3 | 2021 | 365 | 0.210 |
Why?
|
| Hypertension | 3 | 2017 | 1535 | 0.200 |
Why?
|
| Humans | 21 | 2022 | 68618 | 0.200 |
Why?
|
| Estradiol | 1 | 2002 | 176 | 0.190 |
Why?
|
| Prostate | 1 | 2022 | 116 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 1851 | 0.190 |
Why?
|
| Cell Nucleus | 4 | 2007 | 305 | 0.190 |
Why?
|
| India | 1 | 2020 | 41 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 174 | 0.180 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 2 | 2014 | 17 | 0.180 |
Why?
|
| Nurses, Community Health | 1 | 2020 | 6 | 0.180 |
Why?
|
| Fibroblasts | 1 | 2004 | 902 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2020 | 369 | 0.160 |
Why?
|
| Survivors | 2 | 2017 | 256 | 0.150 |
Why?
|
| Informed Consent | 1 | 2019 | 127 | 0.150 |
Why?
|
| Cell Phone | 1 | 2017 | 44 | 0.140 |
Why?
|
| bcl-X Protein | 2 | 2010 | 36 | 0.140 |
Why?
|
| Developing Countries | 1 | 2018 | 106 | 0.140 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2017 | 40 | 0.140 |
Why?
|
| Poverty | 1 | 2018 | 219 | 0.140 |
Why?
|
| Social Stigma | 1 | 2017 | 53 | 0.140 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 25 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.130 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 335 | 0.130 |
Why?
|
| Aging | 2 | 2013 | 911 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2015 | 94 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.120 |
Why?
|
| Cytochromes c | 2 | 2005 | 75 | 0.120 |
Why?
|
| Cysteine | 1 | 2014 | 112 | 0.120 |
Why?
|
| Cytosol | 2 | 2005 | 123 | 0.120 |
Why?
|
| Mice, Nude | 1 | 2014 | 294 | 0.110 |
Why?
|
| Male | 9 | 2022 | 37321 | 0.110 |
Why?
|
| Mitochondria, Heart | 1 | 2013 | 53 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 86 | 0.110 |
Why?
|
| Social Support | 1 | 2015 | 423 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2005 | 271 | 0.110 |
Why?
|
| Cholesterol | 1 | 2013 | 331 | 0.100 |
Why?
|
| Nutrition Surveys | 1 | 2013 | 208 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2016 | 703 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.090 |
Why?
|
| Mice | 3 | 2014 | 8474 | 0.080 |
Why?
|
| Animals | 7 | 2014 | 20881 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2007 | 226 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2800 | 0.080 |
Why?
|
| Transfection | 2 | 2007 | 782 | 0.070 |
Why?
|
| Ghana | 2 | 2017 | 40 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 696 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2013 | 1451 | 0.070 |
Why?
|
| Catalysis | 1 | 2007 | 123 | 0.070 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 442 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 155 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 117 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 284 | 0.070 |
Why?
|
| Neoplasms | 3 | 2008 | 1667 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2003 | 337 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 261 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2005 | 231 | 0.060 |
Why?
|
| Oxidation-Reduction | 3 | 2013 | 567 | 0.060 |
Why?
|
| G2 Phase | 1 | 2005 | 26 | 0.060 |
Why?
|
| Oxygen | 1 | 2007 | 386 | 0.060 |
Why?
|
| Tea | 1 | 2005 | 23 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2005 | 94 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 28 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 47 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 140 | 0.060 |
Why?
|
| Caspases | 1 | 2005 | 194 | 0.060 |
Why?
|
| DNA | 1 | 2007 | 597 | 0.060 |
Why?
|
| Myocardium | 1 | 2010 | 1204 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 852 | 0.060 |
Why?
|
| Tumor Protein p73 | 1 | 2003 | 4 | 0.060 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2003 | 3 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 92 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 61 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 77 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 411 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 82 | 0.050 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2002 | 6 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2002 | 1200 | 0.050 |
Why?
|
| Cell Death | 1 | 2003 | 329 | 0.050 |
Why?
|
| Rats, Inbred F344 | 2 | 2013 | 104 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 50 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 39 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 194 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 499 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2003 | 231 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2007 | 1070 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 901 | 0.050 |
Why?
|
| Ambulances | 1 | 2021 | 27 | 0.050 |
Why?
|
| Middle Aged | 5 | 2017 | 21147 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2005 | 753 | 0.050 |
Why?
|
| Risk Factors | 3 | 2017 | 5731 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2002 | 312 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 756 | 0.050 |
Why?
|
| Proteins | 1 | 2004 | 474 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1174 | 0.050 |
Why?
|
| Aged | 4 | 2017 | 14862 | 0.050 |
Why?
|
| Community Health Workers | 1 | 2020 | 32 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.040 |
Why?
|
| Communication | 1 | 2021 | 329 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 83 | 0.040 |
Why?
|
| Rats | 3 | 2013 | 5300 | 0.040 |
Why?
|
| Female | 5 | 2017 | 38074 | 0.040 |
Why?
|
| Africa, Western | 1 | 2017 | 15 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 247 | 0.030 |
Why?
|
| Angiotensin I | 1 | 2016 | 24 | 0.030 |
Why?
|
| Renin | 1 | 2016 | 96 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2017 | 138 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 319 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Time Factors | 1 | 2003 | 4655 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 782 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1040 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 335 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2010 | 2673 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1619 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1864 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 1342 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 805 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2007 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2279 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1046 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 168 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 196 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1426 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 434 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1664 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2005 | 24 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 92 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 55 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2005 | 71 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 100 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 289 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 7277 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1293 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 694 | 0.010 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2002 | 7 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2002 | 50 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 32 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2002 | 69 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 99 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 251 | 0.010 |
Why?
|
| Microtubules | 1 | 2002 | 104 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 88 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 357 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 140 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 940 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 541 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 489 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 362 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7367 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 954 | 0.010 |
Why?
|
| Adult | 1 | 2013 | 21403 | 0.010 |
Why?
|